WFRF:(Hagman M. A.)
Sökning: WFRF:(Hagman M. A.) > Continuation of flu...
LIBRIS Formathandbok (Information om MARC21)
| Fältnamn | Indikatorer | Metadata |
|---|---|---|
| 000 | 06692naa a2200697 4500 | |
| 001 | oai:DiVA.org:uu-487238 | |
| 003 | SwePub | |
| 008 | 221111s2022 | |||||||||||000 ||eng| | |
| 009 | oai:prod.swepub.kib.ki.se:150847906 | |
| 024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4872382 URI |
| 024 | 7 | a https://doi.org/10.1016/j.esmoop.2022.1004272 DOI |
| 024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1508479062 URI |
| 040 | a (SwePub)uud (SwePub)ki | |
| 041 | a engb eng | |
| 042 | 9 SwePub | |
| 072 | 7 | a ref2 swepub-contenttype |
| 072 | 7 | a art2 swepub-publicationtype |
| 100 | 1 | a Osterlund, P.u Karolinska Institutet4 aut |
| 245 | 1 0 | a Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours :b a multicentre retrospective observational cohort study |
| 264 | 1 | b Elsevier,c 2022 |
| 338 | a electronic2 rdacarrier | |
| 520 | a Background: Capecitabine- or 5-fluorouracil (5-FU)-based chemotherapy is widely used in many solid tumours, but is associated with cardiotoxicity. S-1 is a fluoropyrimidine with low rates of cardiotoxicity, but evidence regarding the safety of switching to S-1 after 5-FU- or capecitabine-associated cardiotoxicity is scarce.Patients and methods: This retrospective study (NCT04260269) was conducted at 13 centres in 6 countries. The primary endpoint was recurrence of cardiotoxicity after switch to S-1-based treatment due to 5-FU- or capecitabine-related cardiotoxicity: clinically meaningful if the upper boundary of the 95% confidence interval (CI; by competing risk) is not including 15%. Secondary endpoints included cardiac risk factors, diagnostic work-up, treatments, outcomes, and timelines of cardiotoxicity.Results: Per protocol, 200 patients, treated between 2011 and 2020 [median age 66 years (range 19-86); 118 (59%) males], were included. Treatment intent was curative in 145 (73%). Initial cardiotoxicity was due to capecitabine (n = 170), continuous infusion 5-FU (n = 22), or bolus 5-FU (n = 8), which was administered in combination with other chemotherapy, targeted agents, or radiotherapy in 133 patients. Previous cardiovascular comorbidities were present in 99 (50%) patients. Cardiotoxic events (n = 228/200) included chest pain (n = 125), coronary syndrome/ infarction (n = 69), arrhythmia (n = 22), heart failure/cardiomyopathy (n = 7), cardiac arrest (n = 4), and malignant hypertension (n = 1). Cardiotoxicity was severe or life-threatening in 112 (56%) patients and led to permanent capecitabine/5-FU discontinuation in 192 (96%). After switch to S-1, recurrent cardiotoxicity was observed in eight (4%) patients (95% CI 2.02-7.89, primary endpoint met). Events were limited to grade 1-2 and occurred at a median of 16 days (interquartile range 7-67) from therapy switch. Baseline ischemic heart disease was a risk factor for recurrent cardiotoxicity (odds ratio 6.18, 95% CI 1.36-28.11).Conclusion: Switching to S-1-based therapy is safe and feasible after development of cardiotoxicity on 5-FU- or capecitabine-based therapy and allows patients to continue their pivotal fluoropyrimidine-based treatment. | |
| 650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
| 650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
| 653 | a cardiac toxicity | |
| 653 | a cardiotoxicity | |
| 653 | a fluoropyrimidines | |
| 653 | a S-1 | |
| 653 | a gastrointestinal cancer | |
| 653 | a colorectal cancer | |
| 700 | 1 | a Kinos, S.u Tampere Univ Hosp, Dept Oncol, Tampere, Finland.;Univ Tampere, Tampere, Finland.4 aut |
| 700 | 1 | a Pfeiffer, P.u Odense Univ Hosp, Dept Oncol, Odense, Denmark.4 aut |
| 700 | 1 | a Salminen, T.u Tampere Univ Hosp, Dept Oncol, Tampere, Finland.;Univ Tampere, Tampere, Finland.4 aut |
| 700 | 1 | a Kwakman, J. J. M.u Amsterdam Univ Med Ctr, Dept Oncol, Amsterdam, Netherlands.4 aut |
| 700 | 1 | a Frodin, J-Eu Karolinska Institutet4 aut |
| 700 | 1 | a Shah, C. H.u Karolinska Univ Hosp, Dept Oncol, Stockholm, Sweden.4 aut |
| 700 | 1 | a Sorbye, H.u Haukeland Hosp, Dept Oncol, Bergen, Norway.;Univ Bergen, Dept Clin Sci, Bergen, Norway.4 aut |
| 700 | 1 | a Ristamaki, R.u Turku Univ Hosp, Dept Oncol, Turku, Finland.;Univ Turku, Turku, Finland.4 aut |
| 700 | 1 | a Halonen, P.u Helsinki Univ Hosp, Dept Oncol, Helsinki, Finland.;Univ Helsinki, Helsinki, Finland.4 aut |
| 700 | 1 | a Soveri, L. M.u Helsinki Univ Hosp, Dept Oncol, Helsinki, Finland.;Univ Helsinki, Helsinki, Finland.4 aut |
| 700 | 1 | a Heerva, E.u Turku Univ Hosp, Dept Oncol, Turku, Finland.;Univ Turku, Turku, Finland.4 aut |
| 700 | 1 | a Algars, A.u Turku Univ Hosp, Dept Oncol, Turku, Finland.;Univ Turku, Turku, Finland.4 aut |
| 700 | 1 | a Barlund, M.u Tampere Univ Hosp, Dept Oncol, Tampere, Finland.;Univ Tampere, Tampere, Finland.4 aut |
| 700 | 1 | a Hagman, H.u Skane Univ Hosp, Dept Oncol, Lund, Sweden.4 aut |
| 700 | 1 | a McDermott, R.u St Vincents Univ Hosp, Dept Oncol, Dublin, Ireland.4 aut |
| 700 | 1 | a O'Reilly, M.u St Vincents Univ Hosp, Dept Oncol, Dublin, Ireland.4 aut |
| 700 | 1 | a Röckert, R.u Uppsala Univ Hosp, Dept Oncol, Uppsala, Sweden.4 aut |
| 700 | 1 | a Liposits, G.u Odense Univ Hosp, Dept Oncol, Odense, Denmark.;Reg Hosp West Jutland, Dept Oncol, Herning, Denmark.4 aut |
| 700 | 1 | a Kallio, R.u Tampere Univ Hosp, Dept Oncol, Tampere, Finland.;Univ Tampere, Tampere, Finland.;Oulu Univ Hosp, Dept Oncol, Oulu, Finland.4 aut |
| 700 | 1 | a Flygare, P.u Sundsvall Hosp, Dept Oncol, Sundsvall, Sweden.4 aut |
| 700 | 1 | a Teske, A. J.u Univ Med Ctr Utrecht, Dept Cardiol, Utrecht, Netherlands.4 aut |
| 700 | 1 | a van Werkhoven, E.u Netherlands Canc Inst, Dept Biometr, Amsterdam, Netherlands.4 aut |
| 700 | 1 | a Punt, C. J. A.u Univ Utrecht, Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Dept Epidemiol, Utrecht, Netherlands.4 aut |
| 700 | 1 | a Glimelius, Bengtu Uppsala universitet,Cancerprecisionsmedicin4 aut0 (Swepub:uu)bengglim |
| 710 | 2 | a Karolinska Institutetb Tampere Univ Hosp, Dept Oncol, Tampere, Finland.;Univ Tampere, Tampere, Finland.4 org |
| 773 | 0 | t ESMO Opend : Elsevierg 7:3q 7:3x 2059-7029 |
| 856 | 4 | u https://doi.org/10.1016/j.esmoop.2022.100427y Fulltext |
| 856 | 4 | u https://uu.diva-portal.org/smash/get/diva2:1710257/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print |
| 856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-487238 |
| 856 | 4 8 | u https://doi.org/10.1016/j.esmoop.2022.100427 |
| 856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:150847906 |
Hitta mer i SwePub
- Av författaren/redakt...
- Osterlund, P.
- Kinos, S.
- Pfeiffer, P.
- Salminen, T.
- Kwakman, J. J. M ...
- Frodin, J-E
- visa fler...
- Shah, C. H.
- Sorbye, H.
- Ristamaki, R.
- Halonen, P.
- Soveri, L. M.
- Heerva, E.
- Algars, A.
- Barlund, M.
- Hagman, H.
- McDermott, R.
- O'Reilly, M.
- Röckert, R.
- Liposits, G.
- Kallio, R.
- Flygare, P.
- Teske, A. J.
- van Werkhoven, E ...
- Punt, C. J. A.
- Glimelius, Bengt
- visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
- MEDICIN OCH HÄLS ...
- och Klinisk medicin
- och Cancer och onkol ...
- Artiklar i publikationen
- ESMO Open
- Av lärosätet
- Uppsala universitet
- Karolinska Institutet
Sök utanför SwePub
- Sök vidare i:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - Nationella bibliotekssystem
- LIBRIS.kb.se
